

For Immediate Release

MedX Health Corp. Announces Refiling of First Quarter Financial Report for 2011

FOR IMMEDIATE RELEASE

Mississauga, Ontario (July 26, 2011) - MedX Health Corp. (TSXV.MDX) announces that as a result of a review by the Ontario Securities Commission in connection with the filing of the Company's unaudited first quarter financial report of 2011 prepared under International Financial Reporting Standards (IFRS) on June 29, 2011 (the First Quarter Report), it has revised and re-filed the First Quarter Report for the three months ended March 31, 2011.

The only change compared to the First Quarter Report that was previously filed, is the inclusion of the opening consolidated statement of financial position as at the date of transition to IFRS (January 1, 2010) as required by subsection 4.3(2) (e) of NI 51-102. The term "audited" has also been removed from the December 31, 2010 heading in the statement of financial position.

The re-filed First Quarter Report which includes the above-noted revisions has been filed with Canadian Securities Regulators on SEDAR and may be viewed on the Company's profile at www.sedar.com

About MedX Health Corp.

MedX is a twelve (12) year old Canadian company, headquartered in Mississauga, Ontario (Toronto), and is a global leader in the design, manufacturing and distribution of quality low lever laser and light therapy technologies for use in numerous medical settings, including rehab/chiropractic, dental, wound care, and veterinary medicine, providing patients with drug free and non-invasive treatment of tissue damage and pain. MedX laser and light products are FDA approved, Health Canada cleared, and CE Mark approved for use in North America as well as the European Union. For a complete profile of MedX Health Corp. and its products visit www.medxhealth.com.

About MoleMate

MoleMate utilizes Siascopy™ composed of (a) a non-invasive, hand-held skin analysis system called the Siascope™ and (b) several versions of proprietary software. The device is intended to be used to scan the patient's skin. Siascopy (Spectrophotometric Intracutaneous Analysis) is a non-invasive skin analysis system, which provides colour bitmaps called 'Siascans' that show the relative location of blood, collagen, and pigment in a lesion on the skin. <http://siascopy.biocompatibles.com/>

The Siascope operates by illuminating the skin with LEDs and measuring the intensity of remitted light. Unlike a biopsy, Siascopy is non-invasive and provides an array of quantitative measurements of the skin that are displayed in graphical form creating a synthesized image called a Siascan. Each Siascan isolates four (4) critical features (Pigment, Dermal Pigment, Blood Supply, and Collagen) viewed over an 11mm diameter area and displays it in conjunction with a magnified 'dermatoscope' view of the lesion. This data is extremely useful as an adjunct in the clinical diagnosis of skin lesions and other skin conditions and as an adjunct in the planning of their treatment.

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward-looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.

Contacts:

Investors:

Steve Guillen
President and Chief Executive Officer
MedX Health Corp. info@medxhealth.com
Phone: (905) 670-4428